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Spinal muscular atrophy is distinct among neurodegenerative conditions of the motor neuron, with onset in developing and
maturing patients. Furthermore, the rate of degeneration appears to slow over time, at least in the milder forms. To investigate
disease pathophysiology and potential adaptations, the present study utilized axonal excitability studies to provide insights into
axonal biophysical properties and explored correlation with clinical severity. Multiple excitability indices (stimulus–response
curve, strength–duration time constant, threshold electrotonus, current–threshold relationship and recovery cycle) were inves-
tigated in 25 genetically characterized adolescent and adult patients with spinal muscular atrophy, stimulating the median motor
nerve at the wrist. Results were compared with 50 age-matched controls. The Medical Research Council sum score and Spinal
Muscular Atrophy Functional Rating Scale were used to deﬁne the strength and motor functional status of patients with spinal
muscular atrophy. In patients with spinal muscular atrophy, there were reductions in compound muscle action potential amp-
litude (P50.0005) associated with reduction in stimulus response slope (P50.0005), conﬁrming signiﬁcant axonal loss. In the
patients with mild or ambulatory spinal muscular atrophy, there was reduction of peak amplitude without alteration in axonal
excitability; in contrast, in the non-ambulatory or severe spinal muscular atrophy cohort prominent changes in axonal function
were apparent. Speciﬁcally, there were steep changes in the early phase of hyperpolarization in threshold electrotonus
(P50.0005) that correlated with clinical severity. Additionally, there were greater changes in depolarizing threshold electro-
tonus (P50.0005) and prolongation of the strength-duration time constant (P = 0.001). Mathematical modelling of the excit-
ability changes obtained in patients with severe spinal muscular atrophy supported a mixed pathology comprising features of
axonal degeneration and regeneration. The present study has provided novel insight into the pathophysiology of spinal muscular
atrophy, with identiﬁcation of functional abnormalities involving axonal K
+ and Na
+ conductances and alterations in passive
membrane properties, the latter linked to the process of neurodegeneration.
doi:10.1093/brain/awr229 Brain 2011: 134; 3185–3197 | 3185
Received April 15, 2011. Revised June 15, 2011. Accepted July 7, 2011. Advance Access publication September 16, 2011
 The Author (2011). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0),
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Keywords: spinal muscular atrophy; axon; excitability
Abbreviations: CMAP = compound motor action potential; SMAFRS = Spinal Muscular Atrophy Functional Rating Scale;
SMN = survival motor neuron; SD = strength–duration time constant
Introduction
Spinal muscular atrophy is a disorder of spinal motor neurons
characterized clinically by the development of muscle weakness
and atrophy. With a carrier frequency of 1 in 50, spinal muscular
atrophy is the leading genetic cause of infant death. Although
mutations in the survival motor neuron 1 (SMN1) gene result in
the spinal muscular atrophy phenotype, secondary to reduction in
the SMN protein (Lefebvre et al., 1995, 1997), the pathophysio-
logical mechanisms remain to be elucidated. Speciﬁcally, while
changes in SMN gene expression and splicing may induce disturb-
ance of membrane transporters, axonal transport, and myelination
pathways (Zhang et al., 2008; Murray et al., 2010), changes in
axonal membrane function have not been investigated.
In terms of identifying the critical pathogenic processes and
timeframes related to nerve degeneration in spinal muscular atro-
phy, there remain a number of unresolved issues (Farrar et al.,
2009). The clinical course may suggest a signiﬁcant early loss of
motor neurons, as manifested by a loss of strength or failure to
gain strength with development. This may be followed by increas-
ing stability of the surviving neurons with slow or absent clinical
deterioration. However, an age dependent decline in compound
muscle action potential (CMAP) amplitudes and motor unit
number estimation values that correlated with functional decline
has been previously demonstrated (Bromberg and Swoboda, 2002;
Swoboda et al., 2005; Lewelt et al., 2010). Alternatively, CMAPs
may remain stable in the face of a decline in motor unit number
estimation values, suggesting lower motor neuron loss with com-
pensatory collateral re-innervation (Swoboda et al., 2005). In fur-
ther contrast, a robust set of motor units may remain functional
for decades (Bromberg et al., 2003). The mechanisms underlying
this spectrum of differential survival and potential compensation of
motor neurons in spinal muscular atrophy remain unknown, but
overall, these clinical changes seem very unusual for a neurode-
generative disorder.
In terms of previous pathophysiological approaches, studies of
motor neurons in a spinal muscular atrophy mouse model have
established hyperexcitability, with alterations in the distribution of
ion channels at the cell membrane hypothesized (Mentis et al.,
2011). To gain insight into spinal muscular atrophy pathophysi-
ology, protocols for testing of axonal membrane function have
recently been developed for clinical assessment (Kiernan et al.,
2000). These techniques have been applied to neurodegenerative
disorders including motor neuron disease, and have established
functional abnormalities of persistent Na
+ conductances and K
+
ion channel function (Bostock et al., 1995; Mogyoros et al., 1998;
Kanai et al., 2006; Vucic and Kiernan, 2006). Upregulation of
persistent Na
+ conductances has been linked to the process of
neurodegeneration and muscle cramping (Kanai et al., 2003),
both features of spinal muscular atrophy. As such, in an attempt
to further clarify the pathophysiological mechanisms underlying
spinal muscular atrophy, the present study utilized axonal excit-
ability techniques, measuring multiple excitability parameters in
order to determine whether abnormalities in axonal membrane
ion channel conductances were a feature of spinal muscular atro-
phy, and whether such abnormalities were linked to the process of
neurodegeneration.
Materials and methods
Patients
Clinical and functional assessments were combined with conven-
tional and specialized neurophysiological assessments in patients
with spinal muscular atrophy types 2 and 3 who expressed homozy-
gous SMN1 deletions. By deﬁnition, patients with spinal muscular at-
rophy type 2 manifested weakness after 6 months of age with the
ability to sit being the maximum motor milestone achieved. Patients
with spinal muscular atrophy type 3 had symptomatic onset after
18 months of age and attained the ability to walk unaided (Munsat
and Davies, 1992). All patients gave informed consent or assent to
the procedures, which were approved by the South Eastern Sydney
and Illawarra Area Health Service Human Research Ethics Committee.
No patient had a history of diabetes or medication use known to
potentially affect peripheral nerve excitability (Krishnan and Kiernan,
2005).
All patients were clinically assessed using the MRC Sum Score
(Medical Research Council, 1976) and the Spinal Muscular Atrophy
Functional Rating Scale (SMAFRS) (Elsheikh et al., 2009).
Speciﬁcally, the MRC sum score incorporated the MRC score of del-
toid, biceps, wrist extensors, abductor pollicis brevis, iliopsoas, quadri-
ceps femoris and tibialis anterior on both sides, with a normal strength
score achieving a total of 70. The SMAFRS assessed the functional
status and a score of 50 was deemed normal. Additionally, subjects
were divided into two subgroups according to SMAFRS score: ‘mild’,
SMAFRS440 or ‘severe’, SMAFRS score440. This classiﬁcation was
chosen as a score 440 indicates ambulation or the ability to stand
with assistance, whereas a score 440 indicates non-ambulatory
patients.
In terms of genetic analysis, genomic DNA was isolated from blood
in all patients with spinal muscular atrophy and homozygous SMN1
deletions conﬁrmed. Determination of SMN2 copy number was under-
taken using previously described techniques (McAndrew et al., 1997;
Smith et al., 2007) to assess potential contribution as a
disease-modifying component (Feldkotter et al., 2002).
Nerve conduction and excitability
studies
Conventional nerve conduction and specialized axonal excitability
studies were undertaken in all patients with spinal muscular atrophy.
Quantitative and qualitative single-unit electromyography was not
routinely undertaken. EMG signals were ampliﬁed and ﬁltered
(3Hz–3kHz) using a GRASS ICP511 AC ampliﬁer (Grass-Telefactor,
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Noise Eliminator, Quest Scientiﬁc Instruments) and sampled at 10kHz
using a 16-bit data acquisition card (National Instruments PCI-MIO-
16E-4). Data acquisition and stimulation delivery was controlled
by QTRACS software (Institute of Neurology). Electrical stimula-
tion was converted to current using an isolated linear bipolar con-
stant current simulator (maximal output 50mA; DS5, Digitimer).
Temperature was measured with a surface probe at the wrist
(Digitech, Jaycar).
Axonal excitability studies were performed using previously
described threshold tracking protocols applied to the median nerve
(Kiernan et al., 2000). Brieﬂy, the cathode was located over the
median nerve at the wrist and the anode 10cm proximally. The
CMAP was recorded using surface electrodes (4620M, Unomedical
Ltd) positioned over the abductor pollicis brevis muscle with the
active electrode at the motor point and the reference electrode 4cm
distal. Amplitude of the CMAP was measured from baseline to nega-
tive peak and the threshold tracking target set to 40% of the max-
imum, utilizing the area of steepest slope of the stimulus response
curve. Threshold tracking follows the changes in the intensity of a
test stimulus required to produce the target potential. Excitability test-
ing incorporated a number of assessments designed to reﬂect different
nodal and internodal properties, from which various excitability meas-
ures could be extracted for analysis. These included: (i) stimulus–re-
sponse curves, which were determined using a 1ms duration test
stimulus increased from zero until supramaximal potentials were at-
tained; (ii) strength–duration properties, which describe the stimulus
strength required to excite nerves as stimulus width is increased from
0.2 to 1ms duration (Weiss, 1901; Bostock, 1983; Mogyoros et al.,
1996); (iii) rheobase, deﬁned as the threshold current for a stimulus of
inﬁnitely long duration was also calculated (Bostock et al., 1998). Both
parameters reﬂect activity of nodal persistent Na
+ conductances
(Mogyoros et al., 1996; Bostock and Rothwell, 1997); (iv) threshold
electrotonus, which measures internodal properties and conduct-
ances and provides an estimate of membrane potential. Prolonged
100ms subthreshold currents were delivered and set to be +40%
and +20% (depolarizing threshold electrotonus) and 40% and
20% (hyperpolarizing threshold electrotonus) of the control thresh-
old current; (v) current–threshold relationship, which measures the
rectifying properties of the axon (Bostock et al., 1998; Kiernan
et al., 2000). The current–threshold relationship was assessed by mea-
suring the change in threshold following the injection of polarizing
currents of 200ms duration, the strength of which was altered in
10% steps from +50% (depolarizing) to 100% (hyperpolarizing)
of the control threshold; and (vi) the recovery cycle, which utilizes
the effects of a supramaximal conditioning stimulus to measure
changes in resting membrane potential at different conditioning-test
intervals (decreasing from 200–2ms) (Kiernan et al., 1996, 2000).
Three stimulus combinations were recorded: (i) unconditioned test
stimulus (1ms duration); (ii) supramaximal conditioning stimulus
alone; and (iii) conditioning and test stimuli in combination. The re-
sponse in (ii) was subtracted online from response in (iii) to eliminate
contamination of the measured CMAP response by the supramaximal
conditioning response at short interstimulus intervals. Ten stimulus
combinations were repeated until four valid estimates were obtained.
The following parameters were measured: (i) relative refractory period
(ms), deﬁned as the ﬁrst intercept at which the recovery curve crosses
the x-axis; (ii) superexcitability (%), deﬁned as the largest reduction
in threshold, peaking at a conditioning-test interval of 510ms; and
(iii) late subexcitability (%), deﬁned as the largest increase in threshold
following the superexcitability period after 10ms.
Electrical model of nerve excitability
To model the excitability changes in motor axons in patients with
spinal muscular atrophy and the effects of altered axonal conductances
and passive membrane properties, mathematical simulations were
undertaken using a model of the human axon (Bostock et al., 1991,
1995; Kiernan et al., 2005). Transient Na
+ channels were modelled
using the voltage-clamp data (Schwarz et al., 1995), and persistent
Na
+ currents were added (Bostock and Rothwell, 1997). The equa-
tions for a single node and internode, representing a spatially uniform
axon, were assessed by integration over successive small time steps
(Euler’s method); (Press et al., 1992; Boland et al., 2009). At times
corresponding to those in human nerve excitability recordings, the
excitability of the model nerve was tested repeatedly to determine
threshold with an accuracy of 0.5%. The discrepancy between the
thresholds determined for the model and those determined from a
sample of real nerves was scored as the weighted sum of the error
terms: [(xm  xn)/sn]
2, where xm is the threshold of the model, xn the
mean and sn the standard deviation of the thresholds for the real
nerves. The weights were the same for all threshold measurements
of the same type (e.g. recovery cycle), and chosen to give an equal
total weight to the different types of threshold measurement: current–
threshold relationship, threshold electrotonus and the recovery cycle.
The standard model was obtained by minimizing the discrepancy be-
tween the model and the normal control data with an iterative least
squares procedure, so that alteration of any of the above parameters
would make the discrepancy worse.
Data analysis
Peripheral nerve excitability parameters were compared with control
data obtained from 50 age-matched subjects (28 males, 22 females;
age range 8–39 years, mean 25.1, not signiﬁcant). Controls were un-
related healthy volunteers recruited from the community. Further sub-
group analysis of the normal control group was undertaken and
demonstrated that there were no signiﬁcant differences in axonal ex-
citability parameters in mid-teen controls, compared to young adult
controls. All controls gave informed consent or assent to the proced-
ures, which were approved by the South Eastern Sydney and Illawarra
Area Health Service Human Research Ethics Committee. While mean
temperature was maintained 432C in subjects with spinal muscular
atrophy and controls, peripheral excitability measures were compen-
sated for temperature before statistical analysis, using the relations
established in controls (Kiernan et al., 2001). All results were expressed
as mean  standard error of the mean (SEM). Data sets were tested
for skew prior to the application of statistical tests. For each parameter
of the multiple excitability measurements, the differences in means
were tested with Student’s unpaired t-test. Correlations between excitabil-
ity and clinical assessments were analysed by Spearman’s rank correlation
coefﬁcient. A P50.05 was considered to be statistically signiﬁcant.
Results
Clinical features
The clinical and genetic features for all 25 patients with spinal
muscular atrophy are summarized in Table 1. The study popula-
tion included 9 males and 16 females (mean age 22.2 years, range
13–40 years; disease duration 5–40 years). There were 11 patients
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muscular atrophy type 3.
Overall, there was a broad spectrum of clinical severity, ranging
from mild to profound weakness and functional impairment, as
reﬂected by the variation in MRC score (range 10–66, median
40) and SMARFRS (range 0–49, median 16). Speciﬁcally, there
was marked clinical variation among patients with spinal muscular
atrophy type 3, with half requiring wheelchair assistance in child-
hood and adolescence and the remainder continuing to walk in
adulthood with mild muscle weakness, such that spinal muscular
atrophy type did not deﬁne current gross motor functional status.
Additionally, there was an overlap of clinical severity among
non-ambulatory subjects with spinal muscular atrophy type 2
and subjects with spinal muscular atrophy type 3. Overall, 32%
of patients from the present cohort were ambulant or able to
stand with assistance, with relatively high levels of function. In
the non-ambulatory group, 89% of patients had undergone
spinal fusion and 33% received nocturnal non-invasive ventilation.
In patients with spinal muscular atrophy, symptomatic muscle
cramps and fasciculations were either infrequent or absent at
the time of investigation.
The age of onset and spinal muscular atrophy phenotype over-
lapped between patients with two or three copies of SMN2. Three
of the four patients with two copies of SMN2 were functionally
the weakest, with strength signiﬁcantly lower in patients with two
copies than in patients with spinal muscular atrophy with three
copies of SMN2 (MRC score: two copies SMN2 26.3  8.0,
three copies SMN2, 43.4  3.8, P50.05). The fourth and
discordant patient with two copies of SMN2 was Patient
18 (Table 1), a 16-year-old male who was independently ambu-
lant until aged 14 years and presently maintained the ability to
stand with support for transfers, highlighting potential individual
variation in copy number and clinical phenotype and the potential
for additional disease modifying factors.
Baseline conventional
neurophysiological assessment
As may have been expected, CMAP amplitude was signiﬁcantly
reduced in the 25 subjects with spinal muscular atrophy when
compared to controls (spinal muscular atrophy, 3.6  1.1mV; con-
trols, 7.7  1.1mV, P50.0005). The threshold currents required
Table 1 Clinical and genetic details of 25 patients with spinal muscular atrophy types 2 and 3
Patients with
spinal muscular
atrophy types 2
and 3
SMN2
copy
number
Age
(years)
SMAFRS MRC
Score
MRC
abductor
pollicis
brevis
Age at loss of
independent
ambulation (years)
Age of
presentation
(years)
12 4 0 0 1 0 2
22 2 7 0 2 3 2
31 1 9 3 2 6 2
43 2 8 6 2 6 3
5– 1 4 2 2 8 2
63 2 1 8 2 9 3
7– 1 5 5 3 4 3
83 2 0 8 3 5 3
9 3 20 13 36 3
10 3 13 14 38 4
11 3 18 17 42 4
Median 20.0 6.0 29.0 3.0
12 2 39 0 25 3 9 2
13 3 17 16 38 4 6 1.5
14 3 19 20 40 4 11 1.5
15 – 15 14 44 4 11 2
16 3 18 24 46 4 7 1.5
17 3 15 29 47 5 14 3
18 2 16 41 50 5 14 4
19 – 31 45 51 5 Ambulant 12
20 3 16 47 56 5 Ambulant 2
21 – 24 47 58 5 Ambulant 11
22 3 36 47 60 5 Ambulant 3
23 3 19 49 62 5 Ambulant 14
24 3 26 48 63 5 Ambulant 12
25 3 22 49 66 5 Ambulant 8
Median 19.0 43.0 50.5 5.0 3.0
The patients were clinically graded using the SMAFRS, with a maximum score of 50 when there is no disability. Muscle strength was clinically assessed using
the Medical Research Council (MRC) for the sum of the MRC score of deltoid, biceps, wrist extensors, abductor pollicis brevis, iliopsoas, quadriceps femoris
and tibialis anterior on both sides and normal strength scores a total of 70. Dash indicates that formal testing of SMN2 copy number was not undertaken at
the time of the study.
3188 | Brain 2011: 134; 3185–3197 M. A. Farrar et al.to elicit a response were similar in patients with spinal muscular
atrophy and controls (spinal muscular atrophy, 3.4  1.1mV; con-
trols, 3.6  1.1mV, not signiﬁcant). The SMAFRS separated sub-
jects into two distinct groups: eight were ambulant or able to
stand with assistance (termed ‘Mild’) and 17 were non-ambulant
(termed ‘Severe’). The CMAP amplitude differed between the
spinal muscular atrophy subgroups and controls (mild spinal mus-
cular atrophy 5.5  1.2mV; severe spinal muscular atrophy
2.8  1.1mV, F = 37.6, P50.0005, Fig. 1).
Measures of axonal excitability
Similar to the variability in clinical and genetic features in the pre-
sent cohort of patients with spinal muscular atrophy, a large range
of changes in axonal excitability were observed. Analysis of the
excitability measures revealed two distinct groups that
corresponded to functional status (Table 2). Accordingly, measures
of axonal excitability were further examined according to disease
severity, to provide further insight into pathophysiology.
Mild spinal muscular atrophy group
A striking ﬁnding was that, despite lower CMAP amplitudes in the
mild spinal muscular atrophy subgroup, multiple measures of ex-
citability appeared similar to controls (Table 2). Of relevance, all
patients with spinal muscular atrophy in this group maintained
MRC grade 5 strength of abductor pollicis brevis, the target
muscle tested.
Severe spinal muscular atrophy group
The slope of the normalized stimulus–response curve was signiﬁ-
cantly reduced in spinal muscular atrophy (spinal muscular atro-
phy, 3.0  1.1; controls, 4.7  1.0, P50.0005). In addition to a
markedly reduced CMAP amplitude, this cohort of patients ex-
hibited prominent excitability abnormalities (Table 2) as follows:
(i) Strength duration properties. The strength-duration time
constant (SD) serves as an indirect measure of nodal per-
sistent Na
+ conductances (Bostock and Rothwell, 1997).
The mean SD was signiﬁcantly prolonged in patients with
severe spinal muscular atrophy compared to controls (spinal
muscular atrophy, 0.49  0.02ms; controls, 0.40  0.01ms,
P40.001, Fig. 2A). As described in the ‘Materials and
methods’ section, peripheral excitability measures were com-
pensated for temperature prior to undertaking statistical
analysis (spinal muscular atrophy 32.2  0.3C; controls
32.9  0.2C). The magnitude of difference for SD re-
mained signiﬁcant even without temperature correction
(raw data: spinal muscular atrophy, 0.50  0.02ms; con-
trols, 0.40  00.01ms, P40.005). Although there was no
signiﬁcant alteration in rheobase (spinal muscular atrophy,
Table 2 Indices in multiple excitability measurements
Spinal muscular atrophy
Normal All Mild Severe
(n = 50) (n = 25) (n =8 ) ( n = 17)
SD (ms) 0.40  0.01 0.47  0.02* 0.39  0.02 0.49  0.02***
Rheobase (mA) 2.5  1.1 2.3  1.1 2.7  1.1 2.2  1.1
TEd40 (peak) (%) 67.4  0.7 70.6  0.1* 68.3  1.5 71.6  1.1**
TEd40 (90–100ms) (%) 45.0  0.6 46.6  1.3 44.1  0.5 48.3  1.9*
TEd20 (peak) (%) 36.8  1.0 44.4  2.3** 37.6  1.6 48.6  2.6****
TEh40 (20–40ms) (%) 91.2  1.3 102.7  3.6*** 86.7  2.4 111.9  3.9****
TEh40 (90–100ms) (%) 117.2  2.4 121.7  5.3 106.9  5.8 131.4  6.8*
TEd40 (undershoot) (%) 19.3  0.6 23.6  1.4** 18.9  1.2 24.4  1.7****
TEh40 (overshoot) (%) 16.1  0.6 24.2  1.6**** 17.7  1.5 26.9  1.7****
Superexcitability (%) 25.9  0.8 26.6  1.6 27.7  1.8  26.6  2.3
Subexcitability (%) 14.9  0.6 18.4  0.9** 15.7  0.8 20.2  1.2****
Resting current-threshold gradient 0.61  0.01 0.56  0.03* 0.6  0.03 0.51  0.03**
Values are represented as mean  SEM.
SD = strength duration time constant; TEd = depolarizing threshold electrotonus; TEh = hyperpolarizing threshold electrotonus. *P50.05; **P50.01; ***P50.005;
****P50.001, compared with normal values.
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Figure 1 Mean data illustrating that the CMAP was
signiﬁcantly reduced in patients with spinal muscular atrophy
compared to controls (*P50.05, **P50.0001).
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and rheobase in healthy controls was maintained in this
cohort of patients with spinal muscular atrophy (R=0.3,
P50.05) (Mogyoros et al., 1998).
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Figure 2 Comparison of multiple measures axonal excitability in the mild and severe spinal muscular atrophy subgroups and normal
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smaller changes in response to stronger hyperpolarizing currents. (F) Recovery cycle of excitability. The most signiﬁcantly altered excit-
ability parameters in the severe spinal muscular atrophy group included hyperpolarizing threshold electrotonus40(20–40) (P50.0005),
depolarizing threshold electrotonus40(peak) (P50.01), depolarizing threshold electrotonus20(peak) (P50.0005), hyperpolarizing
threshold electrotonus40overshoot (P50.0005) and late subexcitability (P50.0005) and are indicated on the ﬁgures. TEd = depolarizing
threshold electrotonus; TEh = hyperpolarizing threshold electrotonus.
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cular atrophy demonstrated steep changes during the early
phases of hyperpolarization and depolarization [hyper-
polarizing threshold electrotonus40(20–40) spinal muscular
atrophy, 111.9  3.9%; controls, 91.2  1.3%,
P50.0005; depolarizing threshold electrotonus40(peak)
spinal muscular atrophy, 71.6  1.1%; controls, 67.4 
0.7%, P50.01; depolarizing threshold electrotonus20
(peak): spinal muscular atrophy, 48.6  2.6%; controls,
36.8  1.0%, P50.0005, Fig. 2B–D]. These changes have
been described as ‘fanning-out’, related to their resemblance
to a Japanese fan (Kaji, 1997). The early fanning out
was partially normalized during hyperpolarization, suggest-
ing more accommodation due to activation of inward recti-
ﬁcation by the hyperpolarization activated current Ih
[hyperpolarizing threshold electrotonus40(90–100): spinal mus-
cular atrophy, 131.4  6.8%; controls, 117.2  2.4%,
P40.01]. The accommodative response to 40% depolariz-
ing currents during threshold electrotonus was complicated
by some axons being excited and activating nodal slow K
+
channels (Trevillion et al., 2007), and overall there was little
change [depolarizing threshold electrotonus40(40–60): spinal
muscular atrophy 51.7  2.0%, controls, 51.3  0.7%, not
signiﬁcant; depolarizing threshold electrotonus40(Accom):
spinal muscular atrophy, 26.6  1.4%, controls, 22.1 
0.6%, P40.001; depolarizing threshold electrotonus40(90–
100): spinal muscular atrophy, 48.3  1.9%, controls,
45.0  0.6%, P50.05]. The threshold electrotonus over-
shoot and undershoot were signiﬁcantly increased in spinal
muscular atrophy [depolarizing threshold electrotonus40
(undershoot): spinal muscular atrophy, 24.4  1.7%; con-
trols, 19.3  0.6%, P50.0005: hyperpolarizing threshold
electrotonus40(overshoot) spinal muscular atrophy,
26.9  1.7%; controls, 16.1  0.6%, P50.0005].
(iii) Current–threshold relationship. The current–threshold rela-
tionship estimates rectifying properties of nodal and inter-
nodal segments of the axon (Bostock et al., 1998).
Additionally, the slope of the curve was used to provide an
estimate of the threshold analogue of input conductance
(Kiernan et al., 2000). The resting current–threshold rela-
tionship slope was signiﬁcantly reduced in subjects with
spinal muscular atrophy [resting current–threshold relation-
ship gradient; spinal muscular atrophy, 0.51  0.03; controls,
0.61  0.01, P40.005], suggesting reduced membrane con-
ductance at the resting membrane potential (Fig. 2E).
(iv) Recovery cycle of excitability. The recovery cycle reﬂects
changes in membrane excitability in response to a supra-
maximal conditioning stimulus (Kiernan et al., 1996). The
initial phase of the recovery cycle, the refractory period, re-
ﬂects inactivation of transient Na
+ channels. The duration of
the relative refractory period was not signiﬁcantly different
when compared to controls (spinal muscular atrophy,
3.1  1.1ms; controls, 2.9  1.0ms, not signiﬁcant).
Superexcitability, a period of increased axonal excitability
due to a depolarizing after potential spreading to the inter-
nodal axolemma (Barrett and Barrett, 1982), was not signiﬁ-
cantly different in patients with spinal muscular atrophy
compared to controls (spinal muscular atrophy, 26.6 
2.3%; controls, 25.9  0.8%, not signiﬁcant). The ﬁnal
phase of the recovery cycle, referred to as the late subexcit-
ability period, probably reﬂects activation of slow K
+ chan-
nels (Waxman and Ritchie, 1993; Kiernan et al., 1996), and
was signiﬁcantly increased when compared to controls (spinal
muscular atrophy, 20.2  1.2%; controls, 14.9  0.6%,
P50.0005, Fig. 2F).
Reproducibility of excitability
measurements
To determine intra-subject variability of excitability measurements
in patients with spinal muscular atrophy, successive recordings
were undertaken in patients without moving the electrodes. The
strength–duration properties, threshold electrotonus, current–
threshold relationship and recovery cycle of excitability graphs were
almost identical. Excitability parameters were highly reproducible
without signiﬁcant variation, similar to previous studies in control
subjects (Kiernan et al., 2000; Tomlinson et al., 2010a).
Correlations with strength and
motor function
Combining measures of axonal excitability and clinical parameters,
it was evident that speciﬁc excitability parameters were signiﬁ-
cantly associated with strength and overall function.
Furthermore, given that patients with spinal muscular atrophy
with lower SMN2 copy number had less strength, it followed
that SMN2 copy number was related to strength and function
(MRC, R=0.58, P=0.01; SMAFRS, R=0.54, P40.05), support-
ing the relevance of excitability measures. A greater hyperpolariz-
ing threshold electrotonus (20–40) was associated with decreased
strength and function (MRC, R=0.69, P50.0005; SMAFRS,
R=0.76, P50.0005, Fig. 3A; SMN2 copy number, R=0.62,
P50.05). Additionally, a prolonged SD was correlated with a
reduction in the MRC sum score (R=0.50, P40.01) and
SMAFRS (R=0.51, P40.005, Fig. 3B). Interestingly the SD
also correlated with the CMAP amplitude (R=0.45, P50.05).
Importantly, clinical measures of severity were also signiﬁcantly
correlated with neurophysiological measures of peripheral disease
burden, namely CMAP amplitude (MRC, R=0.73, P40.0001;
SMAFRS, R=0.62, P50.005, Fig. 3C; SMN2 copy number
R=0.51, P50.05) and stimulus–response slope (MRC,
R=0.67, P40.001; SMAFRS, R=0.68, P50.0005). The effects
of age and axonal excitability were also assessed, and one variable
strongly correlated with age: depolarizing threshold electrotonus
(40–60ms) R=0.76, P50.0005 (Fig. 4).
Mathematical modelling of abnormal
excitability properties
To assist in interpreting the complex changes observed in the clin-
ical nerve excitability measures, a mathematical model of the
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spinal muscular atrophy patient recordings. Since all patients with
severe spinal muscular atrophy showed a similar pattern of abnor-
mality, the most severely affected patients were selected for math-
ematical modelling across four levels of threshold electrotonus.
Depolarizing threshold electrotonus40 was then excluded as
the polarizing current excited some axons, complicating the
recordings.
Taken in isolation, no single parameter change could account
for the spinal muscular atrophy recordings satisfactorily. The best
match was a large reduction in internodal fast K
+ channels (from
110–19.8 units), which reduced the discrepancy by 44% and
depolarized the axons by 1.3mV. A better ﬁt was obtained by
changing two parameters and included reducing the internodal
length by 13%, and reducing internodal fast K
+ channels from
110 to 34 units. These two changes reduced the discrepancy by
55.8% and because there was less reduction in fast K
+ channels,
the axons were only depolarized by 1.0mV.
However, the best ﬁt and most plausible model to explain the
recordings from patients with spinal muscular atrophy was deter-
mined by altering three parameters as follows: internodal length
was reduced by 25%, internodal fast K
+ channels were reduced
from 110 to 5.75 units, while nodal fast K
+ channels were
increased from 19 to 34 units. These three changes reduced the
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ization of 1.2mV. Simulating the full axonal excitability recordings
with this model is depicted in Fig. 5. Overall interpretation incor-
porating mathematical modelling suggested a combination of
changes in passive cable properties and axonal ion channel func-
tion, with a reduction in fast K
+ channels as the most important
channel alteration.
Discussion
The present study has established dysfunction of axonal conduct-
ances and passive membrane properties in patients with spinal
muscular atrophy. In a mild cohort of patients with spinal muscular
atrophy, there was reduction of peak amplitude without speciﬁc
alterations in axonal excitability. In contrast, excitability measures
were most abnormal in clinically severely affected patients with
spinal muscular atrophy. This spectrum of change may suggest
that the excitability changes reﬂected the progression of neurode-
generation and axonal loss. The interpretation of these latter
changes will form the basis of discussion, in relation to pathogenic
processes and potential timeframes related to neurodegeneration
in spinal muscular atrophy.
Prior to analysing ﬁndings from the present study, a potential
limitation of axonal excitability studies relates to the fact that only
surviving axons may be assessed. As such, longitudinal data may
provide clear understanding into the pathophysiology of surviving
motor neurons and their capacity for re-innervation. However,
results from the present study established that nerve excitability
studies were feasible, valid, reproducible and reliable in spinal
muscular atrophy, with all patients successfully completing this
non-invasive procedure. Furthermore, the strong correlation of ex-
citability with clinical and functional measures suggests the poten-
tial for nerve excitability to be developed as a marker of spinal
muscular atrophy severity, for incorporation into assessment of
future treatment approaches.
The SMN2 gene is an almost identical copy of SMN1 and pro-
duces a low level of full length and functional SMN transcripts.
SMN2 gene copy number varies between individuals and modu-
lates the clinical phenotype, being inversely related to disease se-
verity (Wirth et al., 1999; Feldkotter et al., 2002; Mailman et al.,
2002). The determination of SMN2 copy number in the present
series did not precisely predict spinal muscular atrophy type or age
of onset, yet correlated with the clinical phenotype, suggesting
that a higher copy number may be relevant to long-term progress.
Interpretation may, however, be limited as the majority of patients
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Figure 5 Simulation of the excitability changes in patients with spinal muscular atrophy with the mathematical model. (Top) Measures of
axonal excitability for the most severely affected patients with spinal muscular atrophy (black ﬁlled circles) and normal controls (grey
unﬁlled circles). (Bottom) Model of the excitability changes in patients with spinal muscular atrophy. Grey lines represent the standard
model of human motor axons and black lines were generated by the model with internodal length reduced by 25%, internodal fast K
+
channels reduced from 110–5.75 units and nodal fast K
+ channels increased from 19–34 units. These alterations ﬁtted to the most
severely affected patients with spinal muscular atrophy, reduced the discrepancy by 71.8% and involved a membrane depolarization of
1.2mV. (A, E) Threshold electrotonus for 100ms polarizing currents 20% and 40% of the resting threshold. (B, F) Current–threshold
relationship, (C, G) recovery cycles and (D, H) charge–duration plot based on stimuli of 0.2 and 1ms duration with the negative intercept
on the x-axis equating to the strength–duration time constant, and the slope equal to the rheobase.
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dicting outcomes in individual cases is complex. Previous studies
have suggested that not all SMN2 genes are equivalent and that
additional disease-modifying factors appear important in the
pathogenesis of spinal muscular atrophy (Prior et al., 2009). As
such, these ﬁndings highlight the requirement to develop further
biomarkers of disease severity, to improve current understanding
of the pathophysiological mechanisms.
Alterations in potassium conductances
and membrane potential in spinal
muscular atrophy
Signiﬁcantly increased threshold changes in depolarizing threshold
electrotonus were established in patients with severe spinal mus-
cular atrophy from the present study, most likely reﬂecting a re-
duction in fast K
+ conductances. Similar effects have been
described in relation to reduction of fast K
+ conductances in ani-
mal studies utilizing 4-aminopyridine (Baker et al., 1987), a
blocker of fast K
+ channels. Support also comes from studies of
patients with episodic ataxia type 1, related to mutations in the
KCNA1 gene encoding the -subunit of the fast K
+ channel Kv1.1
(Tomlinson et al., 2010b). Reduction in fast K
+ conductances re-
sults in membrane depolarization and shifts slow K
+ channels to a
steeper segment of their activation curve, perhaps underlying the
increases established in late subexcitability (Kiernan and Bostock,
2000). Paradoxically, superexcitability in subjects with spinal mus-
cular atrophy was not altered, possibly reﬂecting complex changes
that developed in passive membrane properties, as suggested by
the results of mathematical modelling.
Separately, a progressive reduction in slow K
+ conductances has
been identiﬁed in patients with spinal muscular atrophy from the
present study. Importantly, loss of K
+ conductances and subse-
quent membrane depolarization has been observed during moto-
neuronal degeneration in amyotrophic lateral sclerosis (Kanai
et al., 2006; Vucic and Kiernan, 2006) and Wallerian degeneration
(Moldovan et al., 2009). These novel ﬁndings in patients with
spinal muscular atrophy are also consistent with a mouse model
of spinal muscular atrophy, demonstrating pre-messenger RNA
splicing defects in the transcripts of genes related to voltage-gated
potassium channels and also axonal transport processes (Zhang
et al., 2008). Further contributions may be derived from disruption
of actin cytoskeletal dynamics and axonal transport processes that
may also contribute to the pathophysiology of spinal muscular
atrophy (Zhang et al., 2003; Bowerman et al., 2010).
Persistent sodium conductances in
spinal muscular atrophy
The present study has established prolongation of SD in patients
with spinal muscular atrophy, which correlated with reduced
muscle strength and function. SD is an indirect measure of per-
sistent Na
+ conductances, which are voltage-dependent and active
at resting membrane potential. Since the resting membrane po-
tential appears depolarized in spinal muscular atrophy (related to
loss of fast K
+ channels as indicated by the modelling), such
changes may be at least part of the reason for the increase in
SD. Separately, an increase in SD may occur during axonal re-
generation or reinnervation (Ritchie, 1982; Kanai et al., 2003;
Nakata et al., 2008; Sawai et al., 2008), related to an increase
in the number or overall conductance of persistent Na
+ channels
(Ritchie, 1982; Nakata et al., 2008). The capacity for axonal
sprouting in spinal muscular atrophy may be supported by clinical
observation, as prolonged periods of stability may occur with par-
tial compensation for concurrent motoneuronal degeneration. In
further support, electromyography has demonstrated increasing
features of re-innervation during the course of the disease
(Hausmanowa-Petrusewicz and Karwanacuteska, 1986). Of fur-
ther relevance, quantitative single unit electromyography data
has demonstrated the presence of small, normal and enlarged
motor units in patients with spinal muscular atrophy, further sup-
porting mixed pathology comprising axonal degeneration and re-
generation (Galea et al., 2001). Alternatively, a prolonged SD
may occur secondary to paranodal demyelination or changes in
nerve geometry precipitated by axonal loss. As there was no evi-
dence of demyelination in motor nerves of spinal muscular atro-
phy, this would seem an unlikely explanation. Furthermore,
assessment of rheobase, a marker sensitive to changes in nerve
geometry, was not signiﬁcantly affected and the negative correl-
ation between the SD and rheobase, as observed in normal con-
trols, was also preserved in spinal muscular atrophy.
The prolonged SD in spinal muscular atrophy would be in
keeping with previous studies of diseased motor neurons, includ-
ing amyotrophic lateral sclerosis, Kennedy Disease and Machado
Joseph Disease (Kanai et al., 2003, 2006; Vucic and Kiernan,
2006, 2007). An increase in nodal persistent Na
+ conductances
in these conditions may underlie membrane instability and lead to
spontaneous activity such as fasciculations and cramp (Kiernan
et al., 2011). In contrast to amyotrophic lateral sclerosis (Kanai
et al., 2006), the increase in SD was not identiﬁed in patients
with spinal muscular atrophy with mild disease but was associated
with clinical severity, suggesting that it would be unlikely to trigger
neurodegeneration in spinal muscular atrophy. A further contrast
to amyotrophic lateral sclerosis is that fasciculations and cramp are
not frequently encountered in early spinal muscular atrophy (Kanai
et al., 2003), although these symptoms may become more prom-
inent during the course of disease (Hausmanowa-Petrusewicz and
Karwanacuteska, 1986). Importantly, upregulation of persistent
Na
+ conductances may provide insight into the mechanisms of
neurodegeneration in spinal muscular atrophy. Speciﬁcally, the ac-
cumulation of intra-axonal Na
+ may trigger reverse operation of
the Na
+–Ca
2+ exchanger and activation of calcium-dependent
enzyme systems such as calpain, phospholipases and protein
kinase C.
Alterations in passive membrane
properties in spinal muscular atrophy
Pathological studies in spinal muscular atrophy have demonstrated
a reduction in axonal diameter, thinly myelinated ﬁbres and distal
axonal sprouting (Chien and Nonaka, 1989). Further, axonal re-
generation is associated with shortened internodes (Ritchie, 1982).
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trotonus were consistent with ‘fanning-out’ (Kaji, 1997) and may
support alterations in passive membrane properties related to
smaller axonal diameter, shortened internodes and thinned
myelin. These structural alterations would reduce the capacitance
of the internodal membrane and the initial rate of change of the
internodal potential (dv/dt = C/i) would become greater, to induce
fanning out of threshold electrotonus waveforms. Previous axonal
excitability studies in regenerated nerve ﬁbres and immature
nerves have demonstrated an early fanning out of hyperpolarizing
threshold electrotonus, reﬂecting a smaller axonal diameter and
relative reduction in internodal capacitance (Yang et al., 2000;
Nodera et al., 2004; Sawai et al., 2008).
The degenerative process in spinal muscular atrophy may be
predicted to affect larger diameter axons initially, progressing to
intermediate and smaller diameter axons. Importantly, the excit-
ability changes observed in the patients with spinal muscular at-
rophy from the present study were not solely attributable to those
expected in smaller diameter axons (Shibuta et al., 2010), which
may be associated with reduced internodal lengths (Ibrahim et al.,
1995) and distinctive distributions of K
+ conductances (Fox and
Ruan, 1989). As such, these ﬁndings further strengthen the inter-
pretation that alterations in membrane conductances identiﬁed in
the present study were not simply markers of disease progression,
but reﬂected separate pathological or adaptive processes, either
contributing to the degenerative process or preserving function
in the face of diminishing motor unit number. As such, these
processes may therefore serve as potential targets for
pharmacotherapy.
The pathophysiology of spinal muscular
atrophy, clinical context and
signiﬁcance
Axonal excitability measures have established dysfunction of axonal
conductances and passive membrane properties in patients with
spinal muscular atrophy. Short internodes are indicative of axonal
regeneration, while the loss of K
+ channels appears to be a fea-
ture of neurodegeneration, supporting a mixed pathology of de-
generation and regeneration. Importantly, excitability changes
were abnormal in the most clinically affected patients, critically
indicating that the excitability changes relate to the process of
neurodegeneration and compensatory partial regeneration.
The clinical course of spinal muscular atrophy suggests a sub-
stantial early loss of motor neurons followed by increasing stability
of the surviving neurons with slow or no clinical deterioration. This
suggestion may be supported by the striking ﬁnding of normal
axonal excitability in the patients with mild spinal muscular atro-
phy from the present study, despite reduction in CMAP. Such
amplitude reductions may reﬂect loss of vulnerable motor neurons,
with relatively preserved function in the surviving axonal popula-
tion. Similar ﬁndings have been demonstrated in amyotrophic lat-
eral sclerosis and Wallerian degeneration, where alterations in
axonal excitability were greatest during disease stages associated
with the largest number of axonal loss (Kanai et al., 2006;
Moldovan et al., 2009). As such, these ﬁndings would support
the capacity for the ongoing existence of a set of robust and
enduring motor neurons, likely related to sufﬁcient SMN protein
to provide physiological function. Altogether, axonal excitability
measures in the surviving axons from the present study may pro-
vide insight into the hypothesis that the rate of neurodegeneration
appears to slow reaching a plateau over time, reﬂecting the cap-
acity for surviving axonal remodelling and collateral sprouting,
concurrent with the process of neurodegeneration. Further these
mechanisms may promote survival in less severe or chronic forms
of spinal muscular atrophy.
Although there remains no effective disease modifying treat-
ment for patients with spinal muscular atrophy, several therapeutic
strategies targeting the unique genomic and molecular basis of the
disease and neuroprotective approaches are currently under devel-
opment. Riluzole, the only disease modifying treatment for amyo-
trophic lateral sclerosis, blocks persistent Na
+ channels (Urbani
and Belluzzi, 2000; Kuo et al., 2005; Cheah et al., 2010) and is
being explored as a potential therapy in spinal muscular atrophy
following an open label study (Russman et al., 2003). Of further
relevance, open label and pilot studies in patients with spinal mus-
cular atrophy have suggested potential beneﬁt with valproic acid
(Weihl et al., 2006; Swoboda et al., 2009). In addition to its
action as a histone deacetylase inhibitor increasing full-length
SMN levels, valproic acid blocks voltage-gated Na
+ channels
and consequently may also provide neuroprotection in spinal mus-
cular atrophy. As such, results from the present study support
further pursuit of these approaches. Clinical trials have held limited
success to date, highlighting challenges in design, including utiliz-
ing sensitive and relevant outcome measures and targeting a pa-
tient group where there is the potential for improvement. As such,
ﬁndings from the present series suggest that axonal excitability
studies may be developed as a marker of spinal muscular atrophy
severity and potentially incorporated into future treatment
approaches.
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